Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
JNJ-90014496 · 1 trial · 3 indications
Occurrence of any AEs, including dose limiting toxicities (DLTs).
Overall response is defined as a PR or CR at any point between the time of JNJ-90014496 infusion until PD or start of subsequent anti-lymphoma therapy, whichever occurs first (per Lugano 2014 guidelines).
| Arm | Type | Description |
|---|---|---|
| JNJ-90014496 | EXPERIMENTAL | Participants will receive intravenous (IV) infusion of autologous JNJ-90014496. The study is no longer enrolling. |
| Name | Type | Description |
|---|---|---|
| JNJ-90014496 | BIOLOGICAL | JNJ-90014496, an autologous dual targeting chimeric antigen receptor (CAR) - T cell therapy targeting Cluster of differentiation (CD)20 and CD19. |
Inclusion Criteria: * Participant must be greater than or equal to (\>=) 18 years of age, at the time of signing informed consent * Tumor must be histologically confirmed cluster of differentiation (CD)19 and/or CD20 positive * Must meet the indications for each subtype in Phase 1b as specified in ...
JNJ-90014496 is an investigational monoclonal antibody being developed for the treatment of B-cell non-Hodgkin lymphoma, including diffuse large B-cell lymphoma. It is currently in Phase 1 clinical development and has not been approved by the FDA.
JNJ-90014496 targets CD19, a protein found on the surface of B cells. By binding to CD19, the antibody is designed to direct the immune system against malignant B cells involved in non-Hodgkin lymphoma.
JNJ-90014496 is being developed by Johnson & Johnson, a pharmaceutical company traded on the New York Stock Exchange under the ticker symbol JNJ.
JNJ-90014496 is in Phase 1 clinical development. It is an investigational drug and has not received FDA approval. The ongoing Phase 1 trial is active but not recruiting participants.
JNJ-90014496 is being studied in a Phase 1 clinical trial with the identifier NCT05421663. This trial enrolls approximately 166 participants with B-cell non-Hodgkin lymphoma and is being conducted in the United States, Australia, Canada, Denmark, Netherlands, South Korea, Spain, and the United Kingdom.